TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12665753

Group type: EXPERIMENTAL
Intervention: Epinephrine injection plus heat probe coagulation
Number of subjects: 185

Group type: COMPARATOR
Intervention: Epinephrine injection plus argon plasma coagulation
Number of subjects: 185
Study: 10741842

Group type: EXPERIMENTAL
Intervention: Indoor environmental conditions related to asthma triggers
Number of subjects: 112
Study: 9280055

Group type: EXPERIMENTAL
Intervention: PSA RT‐PCR
Number of subjects: 90
Study: 8497702

Group type: EXPERIMENTAL
Intervention: Surfactant
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3320381

Group type: EXPERIMENTAL
Intervention: 0.5 ppm NO2 gas exposure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 10
Study: 31532055

Group type: EXPERIMENTAL
Intervention: Multimedia education
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine training (Control)
Number of subjects: 110
Study: 28866384

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed protein formula supplemented with nondigestible oligosaccharides
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard cow's milk formula
Number of subjects: 138
Study: 28116438

Group type: EXPERIMENTAL
Intervention: Minimally invasive extraction
Number of subjects: 160

Group type: COMPARATOR
Intervention: Traditional methods including use of orthodox chisel
Number of subjects: 160
Study: 24297090

Group type: EXPERIMENTAL
Intervention: Sitagliptin + Prednisolone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 23451480

Group type: EXPERIMENTAL
Intervention: Plasma radiofrequency ablation to the anterior extremity of the inferior turbinate
Number of subjects: 153

Group type: COMPARATOR
Intervention: Total inferior turbinate ablation (Control)
Number of subjects: 153
Study: 20224364

Group type: EXPERIMENTAL
Intervention: Maximal sterile barrier precautions (MSBPs)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Standard sterile barrier precaution (SSBP)
Number of subjects: 424
Study: 19263664

Group type: EXPERIMENTAL
Intervention: Topical application of fluor gel
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral washing gel
Number of subjects: 14
Study: 15992564

Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: acamprosate
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: naltrexone plus acamprosate
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study: 11207224

Group type: EXPERIMENTAL
Intervention: Restrictive red blood cell transfusion guidelines without erythropoietin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythropoietin administration
Number of subjects: 0
Study: 9681219

Group type: COMPARATOR
Intervention: Radiotherapy (extended field, generally mantle, 3500 cGy)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Chemotherapy (ABVD: adriamycin, bleomicin, vinblastine and dacarbazine, 6 monthly cycles)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combined therapy (three cycles of ABVD followed by irradiation therapy and three more cycles of chemotherapy)
Number of subjects: 307
Study: 8008405

Group type: EXPERIMENTAL
Intervention: 1 mg of morphine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 2809191

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 or 40 mg twice a day for 12 weeks)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 188
Study: 1222406

Group type: EXPERIMENTAL
Intervention: Heparinized group
Number of subjects: 95

Group type: COMPARATOR
Intervention: Nonheparinized group
Number of subjects: 95
Study: 6996815

Group type: COMPARATOR
Intervention: Zopiclone 3.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zopiclone 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zopiclone 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zopiclone 9 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zopiclone 13.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopiclone (all doses)
Number of subjects: 0
Study: 31476741

Group type: EXPERIMENTAL
Intervention: L-Amino Acid (L-AA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Casein Glycomacropeptide (CGMP-AA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: L-AA and CGMP-AA (immediate post-consumption)
Number of subjects: 40
Study: 28330721

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (20,000 IU weekly)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 94
Study: 25536204

Group type: EXPERIMENTAL
Intervention: Breast reduction group (BRG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 25082115

Group type: EXPERIMENTAL
Intervention: Integrative cognitive behavioural therapy for prolonged grief (PG‐CBT), 20‐25 sessions
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wait list control group (WG)
Number of subjects: 51
Study: 22580858

Group type: EXPERIMENTAL
Intervention: infliximab + methotrexate
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: etanercept or adalimumab
Number of subjects: 66

Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 66
Study: 19013259

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily for a minimum of 48 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 18210989

Group type: EXPERIMENTAL
Intervention: Interspinous process distractors
Number of subjects: 0
Study: 15354103

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preoperative platelet dysfunction (measured by adenosine diphosphate aggregometry)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Algorithm-driven treatment of bleeding
Number of subjects: 90
Study: 11581600

Group type: EXPERIMENTAL
Intervention: 21‐mm and 23‐mm St Jude Medical Hemodynamic Plus valves
Number of subjects: 125

Group type: COMPARATOR
Intervention: 21‐mm and 23‐mm standard cuff valves
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 21‐mm Hemodynamic Plus valves
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 21‐mm and 23‐mm Hemodynamic Plus valves
Number of subjects: 125
Study: 9893590

Group type: EXPERIMENTAL
Intervention: Modified macular grid laser photocoagulation
Number of subjects: 20
Study: 7736484

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily for the first 4 weeks, increasing to 10 mg once daily for the second 4 weeks
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 315
Study: 2927990

Group type: EXPERIMENTAL
Intervention: High-dose nebulized albuterol (0.15 mg/kg per dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-dose nebulized albuterol (0.05 mg/kg per dose)
Number of subjects: 32
Study: 31825704

Group type: EXPERIMENTAL
Intervention: 8-week intensified augmented Berlin-Frankfurt-Münster (BFM) consolidation (IC)
Number of subjects: 5377

Group type: COMPARATOR
Intervention: 4-week standard consolidation (SC)
Number of subjects: 5377

Group type: EXPERIMENTAL
Intervention: Full COG-augmented BFM regimen for SR-high disease
Number of subjects: 5377
Study: 31331773

Group type: EXPERIMENTAL
Intervention: Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Pentavac SD® vaccine
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 405
Study: 28256281

Group type: EXPERIMENTAL
Intervention: Patient Decision Aids (PDAs)
Number of subjects: 17
Study: 26668145

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Traditional laparoscopic cholecystectomy (TLC)
Number of subjects: 552
Study: 23425751

Group type: EXPERIMENTAL
Intervention: Daily administration of the Confusion‐Assessment Method for ICU (intervention service)
Number of subjects: 283
Study: 22091790

Group type: EXPERIMENTAL
Intervention: FFC‐AL intervention implemented by a function focused‐care nurse and a site‐identified champion over 12 months
Number of subjects: 171

Group type: COMPARATOR
Intervention: FFC education only (Control)
Number of subjects: 171
Study: 19672170

Group type: EXPERIMENTAL
Intervention: Acupuncture of Hegu (LI 4)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Needling of cutaneous and muscular point (sham acupuncture)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Without manipulation
Number of subjects: 50
Study: 17405298

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15333852

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Etidronate + Calcium
Number of subjects: 349

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 349
Study: 11483080

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg every other day)
Number of subjects: 21216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21216
Study: 9727365

Group type: EXPERIMENTAL
Intervention: Borderline Hypertension (BHT) subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold pressor test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine levels
Number of subjects: 20
Study: 7980254

Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 63

Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 2644923

Group type: EXPERIMENTAL
Intervention: Single dose of moxalactam (1 g intravenously)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Extended course of moxalactam (1 g intravenously for eight doses)
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: Both groups (single dose and extended course)
Number of subjects: 1027
Study: 1090358

Group type: EXPERIMENTAL
Intervention: Oral 5-FU (20 mg/kg/day for 5 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous 5-FU (13.5 mg/kg/day for 5 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral 5-FU (for malignant hepatomegaly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous 5-FU (for malignant hepatomegaly)
Number of subjects: 100
Study: 31119289

Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 0.50
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 0.62
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 0.75
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 0.88
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 1.00
Number of subjects: 430
Study: 28890331

Group type: EXPERIMENTAL
Intervention: Preoperative opioid counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: No counseling (Control)
Number of subjects: 0
Study: 26721012

Group type: EXPERIMENTAL
Intervention: Group A - Lingual flap retraction in addition to buccal flap
Number of subjects: 380

Group type: COMPARATOR
Intervention: Group B - Retraction of buccal flap only
Number of subjects: 380
Study: 23866554

Group type: EXPERIMENTAL
Intervention: Optimal spectral filter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grey filter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal spectral filter (after crossover)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grey filter (after crossover)
Number of subjects: 0
Study: 21389303

Group type: EXPERIMENTAL
Intervention: Isoviscous, isosweet fat emulsions of increasing fat concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taster status (TS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Segmenting populations by taster status (TS)
Number of subjects: 0
Study: 19028055

Group type: EXPERIMENTAL
Intervention: ePTFE/nitinol self-expanding stent graft
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical femoral to above knee popliteal artery bypass with synthetic graft material
Number of subjects: 100
Study: 17909718

Group type: EXPERIMENTAL
Intervention: Steroid group (30 mg/kg BW methylprednisolone intravenously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (placebo infusion)
Number of subjects: 20
Study: 14973302

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg (single dose)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Telithromycin 400 mg, 600 mg, or 800 mg (repeat dose for 5 days)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Telithromycin (any dosage)
Number of subjects: 76
Study: 11280420

Group type: EXPERIMENTAL
Intervention: Revised Eyes Test
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 15
Study: 9395428

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus CMF (8 cycles)
Number of subjects: 1708

Group type: COMPARATOR
Intervention: CMF alone (9 cycles)
Number of subjects: 1708
Study: 8343782

Group type: EXPERIMENTAL
Intervention: Topical gel ultrasound
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tap water immersion ultrasound
Number of subjects: 20
Study: 3554085

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (MeCCNU + 5‐FU) + Levamisole
Number of subjects: 29

Group type: COMPARATOR
Intervention: Postoperative chemotherapy (MeCCNU + 5‐FU)
Number of subjects: 29
Study: 30196779

Group type: EXPERIMENTAL
Intervention: Eye muscle exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prism management
Number of subjects: 0
Study: 26094549

Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate gel (two‐compound gel) applied once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcipotriol scalp solution applied twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate gel (two‐compound gel)
Number of subjects: 0
Study: 24951495

Group type: COMPARATOR
Intervention: Nicotine replacement therapy
Number of subjects: 315

Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Education level and past quit attempt
Number of subjects: 315
Study: 22293362

Group type: EXPERIMENTAL
Intervention: Stepped-care model for depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stepped-care model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPT constructs 'coherence' and 'cognitive participation'
Number of subjects: 0
Study: 20035494

Group type: EXPERIMENTAL
Intervention: creatine + carbohydrate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: creatine + protein, amino acids, and carbohydrate
Number of subjects: 7

Group type: COMPARATOR
Intervention: creatine alone
Number of subjects: 7
Study: 18364135

Group type: EXPERIMENTAL
Intervention: CartoMerge
Number of subjects: 81

Group type: COMPARATOR
Intervention: CartoXP
Number of subjects: 81
Study: 15751090

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Colchicine prophylaxis
Number of subjects: 153
Study: 12006133

Group type: EXPERIMENTAL
Intervention: Balmandol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eucerin
Number of subjects: 0
Study: 10593379

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 67
Study: 8736649

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 0
Study: 1612362

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 2000 mg daily for 30 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Calcium 2000 mg daily for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 6322674

Group type: EXPERIMENTAL
Intervention: Noncontract therapeutic touch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mimic control intervention
Number of subjects: 0
Study: 30634889

Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 200
Study: 28289280

Group type: EXPERIMENTAL
Intervention: l‐methylfolate 15 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 26872005

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (12 weeks)
Number of subjects: 52
Study: 24258313

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT) with cyproterone acetate (CPA) 100 mg tid
Number of subjects: 366

Group type: COMPARATOR
Intervention: Continuous treatment (CT) with cyproterone acetate (CPA) 100 mg tid
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Intermittent treatment (IT) and Continuous treatment (CT)
Number of subjects: 366
Study: 22437221

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) with SSRIs/SNRIs
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) without SSRIs/SNRIs
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER with SSRIs/SNRIs during double-blind treatment phase
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER without SSRIs/SNRIs during double-blind treatment phase
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER with SSRIs/SNRIs
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER without SSRIs/SNRIs
Number of subjects: 575
Study: 19948944

Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (no gum)
Number of subjects: 107
Study: 18202091

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 300 mg/kg over 24 h
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 16002451

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) administration (7.5 IU or 2.5 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 7
Study: 14641610

Group type: EXPERIMENTAL
Intervention: Theophylline 10 mg/kg bodyweight
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10377504

Group type: EXPERIMENTAL
Intervention: GH treatment for up to 42 months
Number of subjects: 71
Study: 8667301

Group type: EXPERIMENTAL
Intervention: Manipulated prosodic contour of sentences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration and F0 contour of main-clause verb
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated duration of main-clause verb
Number of subjects: 0
Study: 1994787

Group type: EXPERIMENTAL
Intervention: Pemirolast 50 mg bid
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6583195

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 0
Study: 31321800

Group type: EXPERIMENTAL
Intervention: 1,540 nm fractional erbium-glass laser therapy plus topical minoxidil solution applied twice daily for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical minoxidil solution only
Number of subjects: 0
Study: 30646142

Group type: EXPERIMENTAL
Intervention: Long-term nicotine replacement therapy (LT-NRT) for 12 months with 6 follow-up counseling sessions
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard smoking cessation (SSC) treatment for 10 weeks with 4 follow-up counseling sessions
Number of subjects: 398

Group type: COMPARATOR
Intervention: Continuing smokers in SSC
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Continuing smokers in LT-NRT
Number of subjects: 398
Study: 27643726

Group type: EXPERIMENTAL
Intervention: Alive-PD intervention
Number of subjects: 339
Study: 24715706

Group type: EXPERIMENTAL
Intervention: ACE-536 (0.0625-0.25 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ACE-536 (0.25 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23089084

Group type: EXPERIMENTAL
Intervention: Couples treatment approach
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (waited about 3 months for treatment)
Number of subjects: 89
Study: 19443133

Group type: EXPERIMENTAL
Intervention: Interim methadone (IM) maintenance
Number of subjects: 319

Group type: COMPARATOR
Intervention: Waiting list for methadone treatment
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Participants not in methadone treatment at 4 and 10 months
Number of subjects: 319
Study: 17804330

Group type: EXPERIMENTAL
Intervention: Gutta‐percha and Pulp Canal Sealer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resilon, Epiphany primer, and Epiphany
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resilon and Pulp Canal Sealer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EndoRez methacrylate‐based endodontic sealer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Not obturated
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gutta‐percha pellets
Number of subjects: 50

Group type: COMPARATOR
Intervention: Resilon pellets
Number of subjects: 50
Study: 15982798

Group type: EXPERIMENTAL
Intervention: Liposomally encapsulated recombinant human Superoxide Dismutase (lrhSOD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 12077091

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bb‐12 supplementation (bifidobacteria treated group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo group (EHF without supplementation)
Number of subjects: 21
Study: 10207969

Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital nerve block with 0.125% bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peri-incisional infiltration with 0.125% bupivacaine
Number of subjects: 30
Study: 7715290

Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid
Number of subjects: 1493